2011 Scrip 100: CRO 2.0
This article was originally published in Scrip
John Ratliff, chief operating officer of Quintiles, puts his company's success down to its 'four Cs' offering, the decision in 2003 to return to private ownership and its ability to build intimate customer relationships more typical of those offered by small start-ups. And one of these days, writes Joanne Payne, people might stop calling it a CRO.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"